Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
McKinsey
Harvard Business School
McKesson

Last Updated: December 3, 2021

DrugPatentWatch Database Preview

Patent: 9,738,690

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,738,690
Title:Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
Abstract: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.
Inventor(s): Jelcic; Ilijas (Zurich, CH), Martin; Roland (Zurich, CH), Schippling; Sven (Zurich, CH), Sospedra; Mireia (Zurich, CH), Yousef; Sara (Hamburg, DE)
Assignee: UNIVERSITAET ZUERICH (Zurich, CH)
Application Number:14/234,065
Patent Claims:see list of patent claims

Details for Patent 9,738,690

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Try it Free 2031-07-22
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 2002-02-19 ⤷  Try it Free 2031-07-22
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 2001-05-07 ⤷  Try it Free 2031-07-22
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 2014-11-14 ⤷  Try it Free 2031-07-22
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 2004-10-12 ⤷  Try it Free 2031-07-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
AstraZeneca
McKinsey
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.